/clinical/,/clinical/cckm-tools/,/clinical/cckm-tools/content/,/clinical/cckm-tools/content/beacon-protocols/,/clinical/cckm-tools/content/beacon-protocols/gi/,

/clinical/cckm-tools/content/beacon-protocols/gi/name-96670-en.cckm

201708223

page

100

UWHC,UWMF,

Tools,

Clinical Hub,UW Health Clinical Tool Search,UW Health Clinical Tool Search,Beacon Protocols,GI

CSC GI Sunitinib(28D:1-28) VER 8-15-17 (HL 3170)

CSC GI Sunitinib(28D:1-28) VER 8-15-17 (HL 3170) - Clinical Hub, UW Health Clinical Tool Search, UW Health Clinical Tool Search, Beacon Protocols, GI


CSC GI SUNITINIB(28D:1-28) VER: 8-15-17 –  Properties
Pre-Cycle –  8/3/2017 through 8/9/2017 (7 days), Planned
Day 1, Pre-Cycle –  Planned for 8/3/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Pancreatic Neuroendocrine Tumor (Advanced); THERAPY: sunitinib 37.5 mg by mouth daily; CYCLE LENGTH:
28 days (Cycle 1 and 2 only) and 84 days (on subsequent cycles); COURSE: until disease progression
Consent
Verify Consent
Verify informed consent has been obtained.
Pre-Labs
CBC WITHOUT DIFFERENTIAL
Expected: S Approximate, Expires: S+365, Routine
ABSOLUTE NEUTROPHIL COUNT
Expected: S Approximate, Expires: S+365, Routine
ELECTROLYTES
Expected: S Approximate, Expires: S+365, Routine
CREATININE
Expected: S Approximate, Expires: S+365, Routine
MAGNESIUM
Expected: S Approximate, Expires: S+365, Routine
PHOSPHATE
Expected: S Approximate, Expires: S+365, Routine
AST/SGOT
Expected: S Approximate, Expires: S+365, Routine
ALT/SGPT
Expected: S Approximate, Expires: S+365, Routine
ALKALINE PHOSPHATASE
Expected: S Approximate, Expires: S+365, Routine
TSH
Expected: S Approximate, Expires: S+365, Routine
URINALYSIS, NO MICROSCOPY
Expected: S Approximate, Expires: S+365, Normal, Routine
Cycle 1 –  8/10/2017 through 9/6/2017 (28 days), Planned
Day 1, Cycle 1 –  Planned for 8/10/2017
Treatment Plan Information
Reference Information (1)
PANCREATIC NEUROENDOCRINE TUMOR: George S, et al. J Clin Oncol. 2009; 27(19):3154-60
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
8/10/2017 9:46:49 AM Page 1 of 10
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 08/2017CCKM@uwhealth.org

Reference Information (2)
PANCREATIC NEUROENDOCRINE TUMOR: Niccoli P, et al. J Clin Oncol. 2010; 28(15_suppl): Abstract 4000
Treatment Plan Summary
DISEASE: Pancreatic Neuroendocrine Tumor (Advanced); THERAPY: sunitinib 37.5 mg by mouth daily; CYCLE LENGTH:
28 days (Cycle 1 and 2 only) and 84 days (on subsequent cycles); COURSE: until disease progression
Consent
Verify Consent
Verify informed consent has been obtained.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained: CBC, ANC, Creatinine, AST, ALT, Alkaline Phosphatase, Urinalysis.
Treatment Parameters
Hold treatment and notify authorizing prescriber for ANC less than 1000/µL, Platelets less than 75K/µL, Creatinine
Clearance less than 40 mL/min, AST, ALT or Alkaline Phosphatase greater than 2.5 X ULN or Urine Protein greater than
100 mg/dL.
Treatment Parameters (2)
Baseline evaluation of LVEF should be considered for all patients. Periodic evaluations of LVEF should also be
considered for patients with CARDIAC RISK FACTORS. In the presence of clinical manifestations of CHF, discontinuation
of sunitinib is recommended. The dose of sunitinib should be interrupted and/or reduced in patients without clinical
evidence of CHF but have an EF less than 50% and greater than 20% below baseline.
Nursing Procedure, Assessment and Monitoring
Patient Instructions(1)
Sunitinib: Educate patient on hand-foot syndrome, skin and hair discoloration, mucositis, diarrhea and hypertension.
Treatment Medications
See Take Home Medication(s)
Refer to the take home medications section for the following treatment medication(s): sunitinib (dispensed on Day 1 of
Cycle 1 only - subsequent refills will be ordered through the medication activity).
Take Home Medications (delete all that do not apply)
Note to All Staff (1)
Counsel patient to avoid using grapefruit or grapefruit containing products.
sunitinib (SUTENT) 12.5 MG cap
Take  by mouth one time daily. No grapefruit products. Total daily dose = *** mg., R-0, 1 X DAILY starting S, Local
Printer
sunitinib (SUTENT) 25 MG cap
Take  by mouth one time daily. No grapefruit products. Total daily dose = *** mg., R-0, 1 X DAILY starting S, Local
Printer
Follow-Up
DAY 29 FOLLOW-UP
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
8/10/2017 9:46:49 AM Page 2 of 10
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 08/2017CCKM@uwhealth.org

(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC without DIFF, ANC (CBC with DIFF if
drawn locally), Sodium, Potassium, Chloride, Carbon Dioxide, Creatinine, Magnesium, Phosphate, AST, ALT, Alkaline
Phosphatase, Urinalysis without microscopy.
Cycle 2 –  9/7/2017 through 10/4/2017 (28 days), Planned
Day 1, Cycle 2 –  Planned for 9/7/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Pancreatic Neuroendocrine Tumor (Advanced); THERAPY: sunitinib 37.5 mg by mouth daily; CYCLE LENGTH:
28 days (Cycle 1 and 2 only) and 84 days (on subsequent cycles); COURSE: until disease progression
Consent
Verify Consent
Verify informed consent has been obtained.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITHOUT DIFFERENTIAL
Expected: S+28 Approximate, Expires: S+365, Routine
ABSOLUTE NEUTROPHIL COUNT
Expected: S+28 Approximate, Expires: S+365, Routine
ELECTROLYTES
Expected: S+28 Approximate, Expires: S+365, Routine
CREATININE
Expected: S+28 Approximate, Expires: S+365, Routine
MAGNESIUM
Expected: S+28 Approximate, Expires: S+365, Routine
PHOSPHATE
Expected: S+28 Approximate, Expires: S+365, Routine
AST/SGOT
Expected: S+28 Approximate, Expires: S+365, Routine
ALT/SGPT
Expected: S+28 Approximate, Expires: S+365, Routine
ALKALINE PHOSPHATASE
Expected: S+28 Approximate, Expires: S+365, Routine
URINALYSIS, NO MICROSCOPY
Expected: S+28 Approximate, Expires: S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained: CBC, ANC, Creatinine, AST, ALT, Alkaline Phosphatase, Urinalysis.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
8/10/2017 9:46:49 AM Page 3 of 10
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 08/2017CCKM@uwhealth.org

Treatment Parameters
Hold treatment and notify authorizing prescriber for ANC less than 1000/µL or Platelets less than 75K/µL or Creatinine
Clearance less than 40 mL/min or AST greater than 2.5 X ULN or ALT greater than 2.5 X ULN or Alkaline Phosphatase
greater than 2.5 X ULN or Urine Protein greater than 100 mg/dL.
Treatment Parameters (2)
Baseline evaluation of LVEF should be considered for all patients. Periodic evaluations of LVEF should also be
considered for patients with CARDIAC RISK FACTORS. In the presence of clinical manifestations of CHF, discontinuation
of sunitinib is recommended. The dose of sunitinib should be interrupted and/or reduced in patients without clinical
evidence of CHF but have an EF less than 50% and greater than 20% below baseline.
Nursing Procedure, Assessment and Monitoring
Patient Instructions(1)
Sunitinib: Educate patient on hand-foot syndrome, skin and hair discoloration, mucositis, diarrhea and hypertension.
Treatment Medications
Oral Chemotherapy Order Management
For this regimen, sunitinib will be ordered through the medication activity after the initial order.
Follow-Up
DAY 29 FOLLOW-UP
(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC without DIFF, ANC (CBC with DIFF if
drawn locally), Sodium, Potassium, Chloride, Carbon Dioxide, Creatinine, Magnesium, Phosphate, AST, ALT, Alkaline
Phosphatase, Urinalysis without microscopy, TSH
Cycle 3 –  10/5/2017 through 12/27/2017 (84 days), Planned
Day 1, Cycle 3 –  Planned for 10/5/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Pancreatic Neuroendocrine Tumor (Advanced); THERAPY: sunitinib 37.5 mg by mouth daily; CYCLE LENGTH:
28 days (Cycle 1 and 2 only) and 84 days (on subsequent cycles); COURSE: until disease progression
Consent
Verify Consent
Verify informed consent has been obtained.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITHOUT DIFFERENTIAL
Expected: S+28 Approximate, Expires: S+365, Routine
ABSOLUTE NEUTROPHIL COUNT
Expected: S+28 Approximate, Expires: S+365, Routine
ELECTROLYTES
Expected: S+28 Approximate, Expires: S+365, Routine
CREATININE
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
8/10/2017 9:46:49 AM Page 4 of 10
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 08/2017CCKM@uwhealth.org

Expected: S+28 Approximate, Expires: S+365, Routine
MAGNESIUM
Expected: S+28 Approximate, Expires: S+365, Routine
PHOSPHATE
Expected: S+28 Approximate, Expires: S+365, Routine
AST/SGOT
Expected: S+28 Approximate, Expires: S+365, Routine
ALT/SGPT
Expected: S+28 Approximate, Expires: S+365, Routine
ALKALINE PHOSPHATASE
Expected: S+28 Approximate, Expires: S+365, Routine
URINALYSIS, NO MICROSCOPY
Expected: S+28 Approximate, Expires: S+365, Normal, Routine
TSH
Expected: S+28 Approximate, Expires: S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained: CBC, ANC, Creatinine, AST, ALT, Alkaline Phosphatase, Urinalysis.
Treatment Parameters
Hold treatment and notify authorizing prescriber for ANC less than 1000/µL or Platelets less than 75K/µL or Creatinine
Clearance less than 40 mL/min or AST greater than 2.5 X ULN or ALT greater than 2.5 X ULN or Alkaline Phosphatase
greater than 2.5 X ULN or Urine Protein greater than 100 mg/dL.
Treatment Parameters (2)
Baseline evaluation of LVEF should be considered for all patients. Periodic evaluations of LVEF should also be
considered for patients with CARDIAC RISK FACTORS. In the presence of clinical manifestations of CHF, discontinuation
of sunitinib is recommended. The dose of sunitinib should be interrupted and/or reduced in patients without clinical
evidence of CHF but have an EF less than 50% and greater than 20% below baseline.
Nursing Procedure, Assessment and Monitoring
Patient Instructions(1)
Sunitinib: Educate patient on hand-foot syndrome, skin and hair discoloration, mucositis, diarrhea and hypertension.
Treatment Medications
Oral Chemotherapy Order Management
For this regimen, sunitinib will be ordered through the medication activity after the initial order.
Follow-Up
FOLLOW-UP
(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC without DIFF, ANC (CBC with DIFF if
drawn locally), Sodium, Potassium, Chloride, Carbon Dioxide, Creatinine, Magnesium, Phosphate, AST, ALT, Alkaline
Phosphatase, Urinalysis without microscopy, TSH
Cycle 4 –  12/28/2017 through 3/21/2018 (84 days), Planned
Day 1, Cycle 4 –  Planned for 12/28/2017
Treatment Plan Information
Treatment Plan Summary
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
8/10/2017 9:46:49 AM Page 5 of 10
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 08/2017CCKM@uwhealth.org

DISEASE: Pancreatic Neuroendocrine Tumor (Advanced); THERAPY: sunitinib 37.5 mg by mouth daily;
CYCLE LENGTH: 28 days (Cycle 1 and 2 only) and 84 days (on subsequent cycles); COURSE: until disease
progression
Consent
Verify Consent
Verify informed consent has been obtained.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITHOUT DIFFERENTIAL
Expected: S+84 Approximate, Expires: S+365, Routine
ABSOLUTE NEUTROPHIL COUNT
Expected: S+84 Approximate, Expires: S+365, Routine
ELECTROLYTES
Expected: S+84 Approximate, Expires: S+365, Routine
CREATININE
Expected: S+84 Approximate, Expires: S+365, Routine
MAGNESIUM
Expected: S+84 Approximate, Expires: S+365, Routine
PHOSPHATE
Expected: S+84 Approximate, Expires: S+365, Routine
AST/SGOT
Expected: S+84 Approximate, Expires: S+365, Routine
ALT/SGPT
Expected: S+84 Approximate, Expires: S+365, Routine
ALKALINE PHOSPHATASE
Expected: S+84 Approximate, Expires: S+365, Routine
URINALYSIS, NO MICROSCOPY
Expected: S+84 Approximate, Expires: S+365, Normal, Routine
TSH
Expected: S+84 Approximate, Expires: S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained: CBC, ANC, Creatinine, AST, ALT, Alkaline Phosphatase, Urinalysis.
Treatment Parameters
Hold treatment and notify authorizing prescriber for ANC less than 1000/µL or Platelets less than 75K/µL or Creatinine
Clearance less than 40 mL/min or AST greater than 2.5 X ULN or ALT greater than 2.5 X ULN or Alkaline Phosphatase
greater than 2.5 X ULN or Urine Protein greater than 100 mg/dL.
Treatment Parameters (2)
Baseline evaluation of LVEF should be considered for all patients. Periodic evaluations of LVEF should also be
considered for patients with CARDIAC RISK FACTORS. In the presence of clinical manifestations of CHF, discontinuation
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
8/10/2017 9:46:49 AM Page 6 of 10
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 08/2017CCKM@uwhealth.org

of sunitinib is recommended. The dose of sunitinib should be interrupted and/or reduced in patients without clinical
evidence of CHF but have an EF less than 50% and greater than 20% below baseline.
Nursing Procedure, Assessment and Monitoring
Patient Instructions(1)
Sunitinib: Educate patient on hand-foot syndrome, skin and hair discoloration, mucositis, diarrhea and hypertension.
Treatment Medications
Oral Chemotherapy Order Management
For this regimen, sunitinib will be ordered through the medication activity after the initial order.
Follow-Up
FOLLOW-UP
(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC without DIFF, ANC (CBC with DIFF if
drawn locally), Sodium, Potassium, Chloride, Carbon Dioxide, Creatinine, Magnesium, Phosphate, AST, ALT, Alkaline
Phosphatase, Urinalysis without microscopy, TSH
Cycle 5 –  3/22/2018 through 6/13/2018 (84 days), Planned
Day 1, Cycle 5 –  Planned for 3/22/2018
Treatment Plan Information
Treatment Plan Summary
DISEASE: Pancreatic Neuroendocrine Tumor (Advanced); THERAPY: sunitinib 37.5 mg by mouth daily; CYCLE LENGTH:
28 days (Cycle 1 and 2 only) and 84 days (on subsequent cycles); COURSE: until disease progression
Consent
Verify Consent
Verify informed consent has been obtained.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITHOUT DIFFERENTIAL
Expected: S+84 Approximate, Expires: S+365, Routine
ABSOLUTE NEUTROPHIL COUNT
Expected: S+84 Approximate, Expires: S+365, Routine
ELECTROLYTES
Expected: S+84 Approximate, Expires: S+365, Routine
CREATININE
Expected: S+84 Approximate, Expires: S+365, Routine
MAGNESIUM
Expected: S+84 Approximate, Expires: S+365, Routine
PHOSPHATE
Expected: S+84 Approximate, Expires: S+365, Routine
AST/SGOT
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
8/10/2017 9:46:49 AM Page 7 of 10
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 08/2017CCKM@uwhealth.org

Expected: S+84 Approximate, Expires: S+365, Routine
ALT/SGPT
Expected: S+84 Approximate, Expires: S+365, Routine
ALKALINE PHOSPHATASE
Expected: S+84 Approximate, Expires: S+365, Routine
URINALYSIS, NO MICROSCOPY
Expected: S+84 Approximate, Expires: S+365, Normal, Routine
TSH
Expected: S+84 Approximate, Expires: S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained: CBC, ANC, Creatinine, AST, ALT, Alkaline Phosphatase, Urinalysis.
Treatment Parameters
Hold treatment and notify authorizing prescriber for ANC less than 1000/µL or Platelets less than 75K/µL or Creatinine
Clearance less than 40 mL/min or AST greater than 2.5 X ULN or ALT greater than 2.5 X ULN or Alkaline Phosphatase
greater than 2.5 X ULN or Urine Protein greater than 100 mg/dL.
Treatment Parameters (2)
Baseline evaluation of LVEF should be considered for all patients. Periodic evaluations of LVEF should also be
considered for patients with CARDIAC RISK FACTORS. In the presence of clinical manifestations of CHF, discontinuation
of sunitinib is recommended. The dose of sunitinib should be interrupted and/or reduced in patients without clinical
evidence of CHF but have an EF less than 50% and greater than 20% below baseline.
Nursing Procedure, Assessment and Monitoring
Patient Instructions(1)
Sunitinib: Educate patient on hand-foot syndrome, skin and hair discoloration, mucositis, diarrhea and hypertension.
Treatment Medications
Oral Chemotherapy Order Management
For this regimen, sunitinib will be ordered through the medication activity after the initial order.
Follow-Up
FOLLOW-UP
(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC without DIFF, ANC (CBC with DIFF if
drawn locally), Sodium, Potassium, Chloride, Carbon Dioxide, Creatinine, Magnesium, Phosphate, AST, ALT, Alkaline
Phosphatase, Urinalysis without microscopy, TSH
Cycle 6 –  6/14/2018 through 9/5/2018 (84 days), Planned
Day 1, Cycle 6 –  Planned for 6/14/2018
Treatment Plan Information
Treatment Plan Summary
DISEASE: Pancreatic Neuroendocrine Tumor (Advanced); THERAPY: sunitinib 37.5 mg by mouth daily; CYCLE LENGTH:
28 days (Cycle 1 and 2 only) and 84 days (on subsequent cycles); COURSE: until disease progression
Consent
Verify Consent
Verify informed consent has been obtained.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
8/10/2017 9:46:49 AM Page 8 of 10
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 08/2017CCKM@uwhealth.org

IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITHOUT DIFFERENTIAL
Expected: S+84 Approximate, Expires: S+365, Routine
ABSOLUTE NEUTROPHIL COUNT
Expected: S+84 Approximate, Expires: S+365, Routine
ELECTROLYTES
Expected: S+84 Approximate, Expires: S+365, Routine
CREATININE
Expected: S+84 Approximate, Expires: S+365, Routine
MAGNESIUM
Expected: S+84 Approximate, Expires: S+365, Routine
PHOSPHATE
Expected: S+84 Approximate, Expires: S+365, Routine
AST/SGOT
Expected: S+84 Approximate, Expires: S+365, Routine
ALT/SGPT
Expected: S+84 Approximate, Expires: S+365, Routine
ALKALINE PHOSPHATASE
Expected: S+84 Approximate, Expires: S+365, Routine
URINALYSIS, NO MICROSCOPY
Expected: S+84 Approximate, Expires: S+365, Normal, Routine
TSH
Expected: S+84 Approximate, Expires: S+365, Normal, Routine
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained: CBC, ANC, Creatinine, AST, ALT, Alkaline Phosphatase, Urinalysis.
Treatment Parameters
Hold treatment and notify authorizing prescriber for ANC less than 1000/µL or Platelets less than 75K/µL or Creatinine
Clearance less than 40 mL/min or AST greater than 2.5 X ULN or ALT greater than 2.5 X ULN or Alkaline Phosphatase
greater than 2.5 X ULN or Urine Protein greater than 100 mg/dL.
Treatment Parameters (2)
Baseline evaluation of LVEF should be considered for all patients. Periodic evaluations of LVEF should also be
considered for patients with CARDIAC RISK FACTORS. In the presence of clinical manifestations of CHF, discontinuation
of sunitinib is recommended. The dose of sunitinib should be interrupted and/or reduced in patients without clinical
evidence of CHF but have an EF less than 50% and greater than 20% below baseline.
Nursing Procedure, Assessment and Monitoring
Patient Instructions(1)
Sunitinib: Educate patient on hand-foot syndrome, skin and hair discoloration, mucositis, diarrhea and hypertension.
Treatment Medications
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
8/10/2017 9:46:49 AM Page 9 of 10
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 08/2017CCKM@uwhealth.org

Oral Chemotherapy Order Management
For this regimen, sunitinib will be ordered through the medication activity after the initial order.
Follow-Up
FOLLOW-UP
(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC without DIFF, ANC (CBC with DIFF if
drawn locally), Sodium, Potassium, Chloride, Carbon Dioxide, Creatinine, Magnesium, Phosphate, AST, ALT, Alkaline
Phosphatase, Urinalysis without microscopy, TSH
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
8/10/2017 9:46:49 AM Page 10 of 10
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 08/2017CCKM@uwhealth.org